Table 1 Demographic and baseline clinical characteristics of participants
|  | Controls (n = 35) | NLNH (n = 35) | LVH (n = 33) | P value |
|---|---|---|---|---|
Age (years) | 51.34 ± 8.10 | 52.11 ± 7.95 | 51.94 ± 7.50 | 0.913 |
Male sex (number) | 19 (54.3 %) | 18 (51.4 %) | 18 (54.5 %) | 0.959 |
Heart rate (beats/min) | 71.77 ± 9.86 | 75.66 ± 7.92 | 75.94 ± 9.23 | 0.069 |
BMI (kg/m2) | 22.51 ± 2.20 | 22.17 ± 1.95 | 22.09 ± 1.76 | 0.651 |
HD time (months) |  | 12 ± 3 | 27 ± 5# | < 0.001 |
Remove volume (kg) |  | 1.88 ± 1.00 | 52.55 ± 8.34 | 0.143 |
Dry weight (kg) |  | 50.80 ± 7.93 | 2.21 ± 0.80 | 0.380 |
SBP (mmHg) | 120.06 ± 5.72 | 146.06 ± 23.98* | 148.18 ± 15.86* | < 0.001 |
DBP (mmHg) | 69.43 ± 5.94 | 86.40 ± 10.63* | 89.64 ± 9.16* | < 0.001 |
Creatinine (µmol/L) | 63.86 ± 9.44 | 821.89 ± 182.04* | 877.15 ± 177.15* | < 0.001 |
NT-proBNP (pg/ml) | 66.74 ± 22.18 | 1212.06 ± 419.68* | 14551.06 ± 10831.02*# | < 0.001 |
NYHA II-IV (cases) |  | 8 (23 %) | 32 (97 %)# | < 0.001 |
Cause of ESRD | ||||
 Glomerulonephritis (cases) |  | 17 (48.6 %) | 17 (51.5 %) | 0.808 |
 Diabetic Nephropathy (cases) |  | 9 (25.7 %) | 7 (21.2 %) | 0.662 |
 Hypertensive nephrosclerosis (cases) |  | 4 (11.4 %) | 4 (12.1 %) | 0.929 |
 Polycystic kidney (cases) |  | 3 (8.6 %) | 2 (6.1 %) | 0.692 |
 Unknown (case) |  | 2 (5.7 %) | 3 (9.1 %) | 0.594 |
Medication | ||||
 ACEI/ARB (case) |  | 18 (51 %) | 21 (64 %) | 0.309 |
 Calcium channel blockers (case) |  | 22 (63 %) | 24 (73 %) | 0.385 |
 β-Receptor blockers (case) |  | 14 (40 %) | 16 (49 %) | 0.481 |